Biotechblog – Page 883 – Biotechnology business, policy, and more!

Biotech venture capital investments in public equities and performance

How do biotech venture investments in public equities (known as VIPEs) perform? Do they outperform mutual funds and hedge funds? […]

How do biotech stocks behave during the first day of trading? How do they perform in the long-run period? What

After months of development and feedback from customers, DrugPatentWatch is proud to announce the availability of two new datasets: Bulk

This is a guest post from Mark D. Shtilerman1 and Joseph Eng Jr. Dr. Shtilerman is Senior Counsel at Deerfield

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post?

The latest on what the Trump presidency means for health care, hospitals, drug companies, and medical research. Tuesday, Nov. 15

The pharmaceutical industry is regularly chastised for failing to do enough to ensure that people in low and middle-income countries

To date, the Patent Trial and Appeal Board has reached a final decision in eight instituted inter partes review (IPR)

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you

This is a guest post from DrugPatentWatch. Do you have a response to DrugPatentWatch’s post? Respond in the comments section below.